Nvidia-Backed AI Drug Discovery Startup Iambic Therapeutics Files for Nasdaq IPO

Nvidia-Backed AI Drug Startup Files for Nasdaq IPO

Iambic Therapeutics filed for an IPO on the Nasdaq Global Select Market under the ticker symbol "IAM" on Monday, joining a wave of biotech listings that has remained resilient despite broader market uncertainty1

1

. The San Diego-based AI drug discovery company, backed by chip giant Nvidia and the Qatar Investment Authority, plans to use IPO proceeds to advance its cancer drug pipeline through clinical development2

2

. J.P. Morgan, Jefferies, BofA Securities, and Citigroup are serving as lead underwriters for the offering3

3

. The filing did not disclose the number of shares to be offered or an expected price range.

AI Platform to Develop Drug Candidates Through Molecular Superintelligence

Founded in 2019 as Entos, Iambic Therapeutics has developed what it calls a "molecular superintelligence" platform that integrates proprietary AI models with automated lab experiments to discover new drugs2

2

. The biopharmaceutical company's proprietary technologies include Enchant, a multimodal AI model for predicting preclinical and clinical properties, and NeuralPLexer, a generative AI for biomolecular structure prediction4

4

. This AI-driven drug development strategy represents a fundamental shift from legacy drug discovery paradigms by addressing the full journey from hit identification to multiparameter lead optimization to clinical developability.

Three Cancer Drug Candidates Target Solid Tumors

The clinical-stage life sciences company is advancing three early-stage cancer treatments designed to target solid tumors3

3

. Its most advanced candidate, IAM1363, is an experimental cancer pill and oral small molecule HER2 inhibitor currently in an ongoing Phase 1/1b basket clinical trial in patients with advanced HER2-altered solid tumors, including breast cancer, as of September 20262

2

. Iambic expects to file Investigational New Drug applications for two additional programs in the fourth quarter of 2026. IAM217 is a brain-penetrant allosteric inhibitor for KIF18A with potential therapeutic relevance for ovarian cancer and triple-negative breast cancer, while IAM-C1 is a selective dual inhibitor of cyclin-dependent kinases 2 and 43

3

.

Strong Investor Backing and Strategic Pharma Partnerships

Since its inception, Iambic Therapeutics has raised approximately $461.8 million in capital through September 18, 2026, from technology- and healthcare-focused investors1

1

. Besides Nvidia and Qatar Investment Authority, the company counts investment firms Catalio, Nexus Ventures, Q Healthcare Holding, and Coatue Ventures among its five largest shareholders2

2

. The company has also established partnerships with major pharmaceutical firms. Earlier on the day of its IPO filing, Iambic and drugmaker AbbVie unveiled a multi-year collaboration to accelerate AI-driven discovery of small molecule therapies1

1

. The company also holds partnerships with Takeda Pharmaceutical Company Limited and Jazz Pharmaceuticals2

2

.

Revenue Growth Amid Widening Losses in Biotech Boom

Iambic's full-year 2025 revenue reached $9.4 million, up from $1.2 million in 2024, though its net loss widened to $77.3 million from $47.9 million over the same period2

2

. The company plans to use proceeds from the Nasdaq IPO, along with existing cash, to continue advancing its three cancer drug candidates through clinical development, with any remaining funds directed toward general operating costs. The IPO comes as the biotech boom continues to roll on, with the sector remaining relatively insulated from broader market pressures. According to Matt Kennedy, senior strategist at Renaissance Capital, "All five of the year's best-performing IPOs ($50 million deal size and above) are biotechs. Much of that is being driven by drug advancement and M&A"1

1

. Drug developers Retension Pharmaceuticals and TRex Bio also filed for US IPOs on Friday, while ADARx Pharmaceuticals launched its roadshow earlier on Monday, underscoring the sector's momentum despite uncertainty surrounding geopolitical tensions and interest rate pressures.